-

Results Show Treatment With Ondine’s Nasal Photodisinfection Dramatically Reduced Covid-19 Rates at Canadian Meat Processing Plant

VANCOUVER, British Columbia--(BUSINESS WIRE)--Newly published research in the journal Public Health Practice shows that a weekly program of nasal photodisinfection implemented at a major Western Canada meat packing plant, alongside standard safety measures recommended by the US Centre for Diseases Control and Prevention (“CDC”), reduced the expected COVID-19 positivity rate by over 99%, from 1,344 expected positive PCR tests to 3 positive PCR tests out of over 21,000 administered tests over a seven-month period.

Meat processing plants worldwide experienced a disproportionately greater incidence of COVID-19 than surrounding communities, despite implementing safety precautions.

The extraordinary reduction in the COVID-19 positivity rate permitted the plant to continue to operate without shutdown or disruption. Authors also noted that COVID-19 rates were lowered in populations surrounding the plant, potentially as a result of reduced transmission from the large worker population to the community. The voluntary, five-minute treatment was well received by the workforce, with a compliance rate of over 75% by the end of the seven-month study. No serious side effects from nasal photodisinfection were reported.

Professor Richard Rusk from the University of Manitoba and a joint author of the paper commented:

“This study suggests that nasal photodisinfection can provide safe and effective SARS-CoV-2 viral suppression when deployed in an industrial workplace setting. Outcomes of the study demonstrated significant reduction of COVID-19 rates compared to surrounding community rates, implying substantially reduced acute and long-term illness, disability, and death rates in plant employees. The intervention proved safe with repeated weekly administrations and was easy to implement and well received by the workforce. This has strong positive implications for viral outbreak suppression in other industries and employee demographics across the world.”

Read more.

**ENDS**

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered life sciences company that is the leader in photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include treatments for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.

Contacts

Ondine Biomedical Inc.
Angelika Vance, Corporate Communications

+001 (604) 838 2702

Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard
+44 (0)77 1000 5910

Ondine Biomedical Inc.


Release Summary
Weekly nasal photodisinfection of 1,500 workers in a meat processing plant in Western Canada reduced infection to only 3 positive PCR tests.
Release Versions

Contacts

Ondine Biomedical Inc.
Angelika Vance, Corporate Communications

+001 (604) 838 2702

Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard
+44 (0)77 1000 5910

More News From Ondine Biomedical Inc.

Ondine Biomedical's US $11M Fundraise Enables a Q4 2024 Start of Its Pivotal Phase 3 US Trial

VANCOUVER, British Columbia--(BUSINESS WIRE)--Ondine Biomedical announces that it is accelerating its US Phase 3 trial following its recent successful raise of Cdn $16 million (£9m, US $11m)....

Ondine Successfully Raised C$4.91 Million to Support Acceleration of Its Commercial Rollout of Nasal Decolonization to Prevent Healthcare-associated Infections

VANCOUVER, Canada--(BUSINESS WIRE)--Following its successful fundraising of C$4.91 million (US$3.62), Canadian life sciences company Ondine Biomedical Inc. will continue accelerating commercialisation of its proven nasal photodisinfection technology. This cutting-edge technology replaces topical antibiotics for the prevention of healthcare-associated infections (HAIs) and kills all types of pathogens – bacteria, viruses and fungi – without causing antimicrobial resistance. The company has confi...

Ondine Biomedical’s photodisinfection recommended as standard of care

VANCOUVER, British Columbia--(BUSINESS WIRE)--Canadian life sciences company, Ondine Biomedical Inc., reports that an independent, peer-reviewed research paper, “Effectiveness of prophylactic intranasal photodynamic disinfection therapy and chlorhexidine gluconate body wipes for surgical site infection prophylaxis in adult spine surgery” from Vancouver General Hospital (“VGH”) has been published in the Canadian Journal of Surgery. The study spanned an eight-year period and involved 13,493 patie...
Back to Newsroom